---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000055"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:49:45.883671+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel

## Summary
- Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.
- Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.
- Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.
- ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.
- ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024.

## SEC filing metadata
- accession: 0001737287-24-000055
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/0001737287-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/allo-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000055
- JSON: https://secwatch.observer/filing/0001737287-24-000055.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.